Shares in StemCells (NSDQ:STEM) initially soared some 600% this week after the company initiated a reverse merger with Microbot Medical, after the failure of a Phase II trial of StemCells’ spinal cord injury treatment. The merger also saw the resignation of CEO Ian Massey, CFO Gregory Schiffman and a trio of board members, as the team led by […]